CDKN1A and cancer: miR‐93‐5p is an oncomiR that can activate the PI3K/Akt pathway, being involved in cancer cell proliferation, invasion, and resistance to apoptosis.[36, 37] It also acts as a target key regulator of the epithelial‐mesenchymal transition and Wnt signaling pathways.[38] In line with these reports, our bioinformatics and luciferase reporter assays demonstrated that RBC‐derived miR‐93‐5p directly targets tumor suppressors such as PTEN, TP53INP1, THBS2, and CDKN1A.